Pall Corp

Pall — FY2012 Earnings Presentation

32 slides from Pall's earnings presentation, Sep 13, 2012

  1. Slide 1: Q4 and Full Year FY 2012 Financial Results

    Better Lives. Better Planet.SM Q4 and Full Year FY 2012 Financial Results September 13, 2012 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for fiscal year 2012 are preliminary until the Company's Form 10-K is filed with the Securities and Exchange Commission on or before October 1

  3. Slide 3: Conference Call Replay Info

    3 Conference Call Replay Info • Toll-Free: 855.859.2056 • International: 404.537.3406 • Conference ID: 26044759 • Internet: www.pall.com/investor

  4. Slide 4: Agenda

    4 Agenda • Pall Outlook and FY 2012 Summary • Q4 and FY 2012 Performance • FY 2013 Guidance • Q&A All remarks in this presentation are on a “Continuing Operations” basis, which excludes the results of the Blood product line divestiture, unless indicated otherwise.

  5. Slide 5: FY 2012 Summary & Outlook

    5 FY 2012 Summary & Outlook • Record quarter despite headwinds • Progress on People, Process and Technology initiatives • Capital allocation priorities • Structural cost improvement initiative • Macro environment and headwinds Value Creation in a Volatile Economy

  6. Slide 6: Financial Overview

    6 $2,517 $2,672 $719 $722 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 Revenue % Growth Excluding FX Q4 Full Year Financial Overview (a) See Reconciliation of Non-GAAP Financial Measures to their GAAP Counterparts in Appendix (b) Free Cash Flow from total operations Dollars in Millions, except EPS dat

  7. Slide 7: Sales by Segment

    7 Fourth Quarter Life Sciences Consumables $306 +13.7% Industrial Consumables $301 +4.6% Industrial Systems $87 +7.3% Life Sciences Systems $28 (-30.5%) 42% 42% 12% 4% Sales by Segment Life Sciences Consumables $1,133 +7.0% Industrial Consumables $1,159 +5.5% Full Year Industrial Systems $259 +14.8%

  8. Slide 8: Life Sciences Q4 Sales & Orders

    8 Life Sciences Q4 Sales & Orders Sales Consumables • BioPharmaceuticals +19.8% − Strength in the biotech sector − ForteBio acquisition added $7mm (~4%) • Food and Beverage +4.5% − Organic growth ~+12% − New applications and products − Low margin systems rationalization • Medical +1.9% − Driven by I

  9. Slide 9: Life Sciences Full Year Sales & Orders

    9 Life Sciences Full Year Sales & Orders Sales Consumables • BioPharmaceuticals +12.1% – ForteBio acquisition added $13mm (~2%) • Food and Beverage (-2.5%) − Organic growth ~+4% • Medical (-1.3%) − Reduced hospital spending due to governmental/budget pressure Systems • Double-digit growth in BioPhar

  10. Slide 10: Industrial Q4 Sales & Orders

    10 Industrial Q4 Sales & Orders Sales Consumables • Process Technologies (-0.2%) − Lower volume of capital goods shipments in Energy Market − Increased sales to Machinery & Equipment OEMs • Aerospace +21.6% − Military +31% and Commercial +11% − Strong demand for spares • Microelectronics +2.2% − Inc

  11. Slide 11: Industrial Full Year Sales & Orders

    11 Industrial Full Year Sales & Orders Sales Consumables • Process Technologies +8.0% − Growth in all underlying markets • Aerospace +12.2% − Military +20.5% and Commercial +3.8% • Microelectronics (-3.5%) − Semiconductor production in Asia remained weak − Displays weak; data storage negatively impa

  12. Slide 12: Q4 Sales & Orders by Region

    12 Q4 Sales & Orders by Region Dollars in millions Sales and orders changes exclude FX Americas Sales • Past due customer order reduction • Acquisitions +~4% • Organic growth +~7% • Latin America +~25%−aided by Brazilian distributor acquisition Orders • Recovery demand from Q3 • Strong growth in Lat

  13. Slide 13: Segment Performance: Gross and Segment Margin

    13 0% 10% 20% 30% 40% 50% Q4 Year Q4 Year 46.0% +280 bps 43.2% 45.9% +10 bps 45.8% 17.4% +490 bps 12.5% 14.0% +30 bps 13.7% Gross Margin Segment Margin Segment Performance Life Sciences Q4 • BioPharm consumables favorable mix, pricing and sales channel change drove Q4 gross margin improvement; FX he

  14. Slide 14: Financial Overview and Pro forma EPS Bridge

    14 $2,517 $2,672 $719 $722 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 Revenue % Growth Excluding FX Q4 Full Year Financial Overview (a) See Reconciliation of Non-GAAP Financial Measures to their GAAP Counterparts in Appendix Dollars in Millions, except EPS data $2.42 $2.80 $0.65 $0.86 $- $0.50 $1.00

  15. Slide 15: Cash Flow and Working Capital

    15 Cash Flow and Working Capital Full Year FY12 Full Year FY11 Operating Cash Flow 475$ 430$ CapEx (159) (161) Free Cash Flow 316$ 269$ Other Significant Uses of Cash: Acquisition of businesses (168)$ -$ Dividends (89) (78) Repayment under Financing Facilities (10) (89) Stock Buybacks (121) (150) Da

  16. Slide 16: Impact of the Blood Divestiture

    16 Impact of the Blood Divestiture • Completed the divestiture of the business assets of the blood collection, filtration and processing product lines on August 1, 2012 • Received ~$440mm(1) of cash proceeds, after pro forma tax, upon closing • FY 2012 Blood Financial Results: – Revenue ~$230mm – Op

  17. Slide 17: FX Risk

    17 FX Risk BOY = Beginning of year, Gross profit numbers in Dollars in millions (a) As at July 31, 2012 U S D a n d GBP E q u iv a le n t o f E u ro ( a ) 14% 11% FY2012 Weighted Average 2013 Assumptions Δ % GBP/Euro 0.84 0.79 (-6%) USD/Euro 1.32 1.25 (-5%) Currency Pair Analysis • We continue to ha

  18. Slide 18: Challenging Macro Environment

    18 Challenging Macro Environment Global macroeconomic concerns are exacerbated by negative real growth rates Nominal GDP Growth CPI Inflation Real GDP Growth(1) 2010 2011 2012E 2013E Source: BofA Merrill Lynch Global Economic Weekly report dated September 7, 2012. (1) Real GDP growth calculated as N

  19. Slide 19: FY 2013 Outlook

    19 Revenue • Low to mid single digit growth Pro Forma EPS • $3.05 – $3.25 • Represents growth of 9% – 16% • Estimate excludes Discrete Items, future acquisitions and related costs FY 2013 Outlook Other Key Assumptions • Gross Margins − 20-40 bps improvement − Includes ~$10mm of structural cost impro

  20. Slide 20: FY 2013 Outlook: 2012 to 2013E EPS Walk

    20 FY 2013 Outlook (cont’d) 2012 to 2013E EPS Walk Low High FY 2012 EPS 2.80$ 2.80$ Sales Growth 0.20 0.41 Structural Cost Improvement 0.30 0.30 FX (0.22) (0.24) Tax Rate (0.03) (0.03) Share Repurchase 0.10 0.11 R&D Investment (0.10) (0.10) FY 2013E EPS 3.05$ 3.25$

  21. Slide 21: Appendix

    Better Lives. Better Planet.SM Appendix

  22. Slide 22: Appendix: Earnings from Continuing and Discontinued Operations

    22 Appendix: Earnings from Continuing Operations Reconciliation of Non-GAAP Financial Measures Discontinued Operations Fourth Quarter Diluted EPS as reported 0.64$ 0.76$ 0.09$ Tax Adjustments (0.01) (0.16) - Interest Adjustments (0.02) (0.03) - Restructuring and Other Charges (ROTC), after pro forma

  23. Slide 23: Appendix: Q4 Life Sciences Sales By Market & Technology

    23 Appendix: Q4 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q4 FY12 Q4 FY12 Estimated Impact of FX Q4 FY12 Estimate Excluding FX Q4 FY11 % Change Excluding FX Consumables Sales: BioPharmaceuticals 204.8$ (13.5)$ 218.3$ 182.3$ 19.8% Medical 51.5 (3.6) 55.1

  24. Slide 24: Appendix: Full Year Life Sciences Sales By Market & Technology

    24 Appendix: Full Year Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year FY12 Full Year FY12 Estimated Impact of FX Full Year FY12 Estimate Excluding FX Full Year FY11 % Change Excluding FX Consumables Sales: BioPharmaceuticals 754.9$ (8.3)$ 763.2 681

  25. Slide 25: Appendix: Q4 Industrial Sales By Market & Technology

    25 Appendix: Q4 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q4 FY12 Q4 FY12 Estimated Impact of FX Q4 FY12 Estimate Excluding FX Q4 FY11 % Change Excluding FX Consumables Sales: Process Technologies 151.5$ (9.8)$ 161.3$ 161.5$ (0.2%) Aerospace 66.6 (2.0) 68.

  26. Slide 26: Appendix: Full Year Industrial Sales By Market & Technology

    26 Appendix: Full Year Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Full Year FY12 Full Year FY12 Estimated Impact of FX Full Year FY12 Estimate Excluding FX Full Year FY11 % Change Excluding FX Consumables Sales: Process Technologies 627.6$ (6.4)$ 634.0$ 587

  27. Slide 27: Appendix: Q4 Sales by Segment and Region

    27 Appendix: Q4 Sales by Segment and Region Reconciliation of Non-GAAP Financial Measures Q4 FY12 Q4 FY12 Estimated Impact of FX Q4 FY12 Estimate Excluding FX Q4 FY11 % Change Excluding FX Life Sciences Sales: Americas 114.4$ (1.5)$ 115.9$ 94.8$ 22.2% Europe 146.1 (19.5) 165.6 168.9 (2.0%) Asia 74.2

  28. Slide 28: Appendix: Q4 Orders by Technology

    28 Appendix: Q4 Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in millions Q4 FY12 Q4 FY12 Estimated Impact of FX Q4 FY12 Estimate Excluding FX Q4 FY11 % Change Excluding FX Life Sciences Orders: Consumables 299.6$ (22.1)$ 321.7$ 281.2$ 14.4% Systems 39.8 (2.9) 42.7 37.4

  29. Slide 29: Appendix: Full Year Orders by Technology

    29 Appendix: Full Year Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in millions Full Year FY12 Full Year FY12 Estimated Impact of FX Full Year FY12 Estimate Excluding FX Full Year FY11 % Change Excluding FX Life Sciences Orders: Consumables 1,156.3$ (12.5)$ 1,168.8$ 1,0

  30. Slide 30: Appendix: Q4 Operating Profit

    30 Appendix: Q4 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q4 FY12 Q4 FY11 Life Sciences segment profit 86.1$ 78.8$ Industrial segment profit 67.6 48.5 Total segment profit 153.7$ 127.3$ General corporate expenses (14.3) (15.4) Ope ating profit 139.4$ 111.9$ % of

  31. Slide 31: Appendix: Full Year Operating Profit

    31 Appendix: Full Year Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Full Year FY12 Full Year FY11 Life Sciences segment profit 319.3$ 292.5$ Industrial segment profit 198.8 182.7 Total segment profit 518.1$ 475.2$ General corporate expenses (64.1) (61.1) Operating

  32. Slide 32: Better Lives. Better Planet.

    Better Lives. Better Planet.SM www.pall.com/green

Pall — FY2012 Earnings Presentation on 6ix